Online citations, reference lists, and bibliographies.
← Back to Search

Incorporation Of Biomarker Assessment In Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments

E. Galanis, W. Wu, J. Sarkaria, S. Chang, H. Colman, D. Sargent, D. A. Reardon
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.
This paper references
10.1097/CAD.0b013e3281de727e
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer
I. Cree (2007)
10.1093/JNEN/63.4.314
Prognostic Value of 1p, 19q, 9p, 10q, and EGFR‐FISH Analyses in Recurrent Oligodendrogliomas
K. Fallon (2004)
10.1215/15228517-2006-005
Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma.
A. Brandes (2006)
10.1056/NEJMOA043330
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
R. Stupp (2005)
10.1111/j.1750-3639.2004.tb00044.x
Oligodendroglial Tumors: Refinement of Candidate Regions on Chromosome Arm 1p and Correlation of 1p/19q Status with Survival
J. Felsberg (2004)
10.1016/S1470-2045(09)70025-7
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
R. Stupp (2009)
10.1200/JCO.2009.23.6497
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
W. Wick (2009)
10.1200/JCO.2000.18.3.636
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
J. S. Smith (2000)
10.1093/JNCI/88.20.1456
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
D. Hayes (1996)
10.1038/nrd1927
Bayesian clinical trials
D. Berry (2006)
10.1002/ijc.20575
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
Maria Möllemann (2005)
10.1200/JCO.2008.17.5984
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
M. J. van den Bent (2009)
10.1016/j.ccr.2009.12.020
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
R. Verhaak (2010)
10.1200/JCO.2009.24.1034
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
M. J. van den Bent (2009)
10.1158/0008-5472.CAN-06-1796
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
R. Jenkins (2006)
10.1200/JCO.2005.04.6078
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
M. J. van den Bent (2006)
10.1023/A:1006197805041
Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?
D. Hayes (2004)
10.1200/JCO.2005.04.3414
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
G. Cairncross (2006)
10.1093/neuonc/nop007
A multigene predictor of outcome in glioblastoma.
H. Colman (2010)
10.1002/cncr.11187
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
M. J. van den Bent (2003)
10.1016/J.CCR.2006.02.019
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
H. Phillips (2006)
10.1056/NEJMOA051918
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
I. Mellinghoff (2005)
10.1200/JCO.2009.21.9832
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
M. Sanson (2009)
10.1056/NEJMOA043331
MGMT gene silencing and benefit from temozolomide in glioblastoma.
M. Hegi (2005)
10.1038/bjc.1994.192
Statistical aspects of prognostic factor studies in oncology.
R. Simon (1994)
10.1158/1535-7163.MCT-08-0854
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
M. Clarke (2009)
10.1200/JCO.2005.01.112
Clinical trial designs for predictive marker validation in cancer treatment trials.
D. Sargent (2005)
10.1053/SONC.2002.32896
Issues and barriers to development of clinically useful tumor markers: a development pathway proposal.
M. Hammond (2002)



This paper is referenced by
10.3390/ijms18010150
IQGAP1 in Podosomes/Invadosomes Is Involved in the Progression of Glioblastoma Multiforme Depending on the Tumor Status
Deborah Rotoli (2017)
A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents
J. Woodcock (2012)
10.2217/fon.12.111
The future of glioma treatment: stem cells, nanotechnology and personalized medicine.
M. Rahman (2012)
10.5414/NP300904
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
M. Bienkowski (2015)
10.1161/CIRCULATIONAHA.113.008428
Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease.
B. W. McCrindle (2014)
10.4172/2157-7412.1000E114
Frontiers in Suicide Gene Therapy of Cancer.
M. Malecki (2012)
10.1016/S1470-2045(11)70406-5
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group.
E. Galanis (2012)
10.1007/978-3-319-15811-2_7
Next-Generation Sequencing for Cancer Biomarker Discovery
A. Desai (2015)
10.3390/jpm7010001
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Miranta Antoniou (2017)
10.1007/978-3-030-31503-0_8
Clinical Application of Molecular Features in Therapeutic Selection and Drug Development
R. Lu (2019)
Thrombosis in Pediatric Cardiology and Congenital Heart Disease Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on Challenges and Priorities for Research: A Report From the National Heart, Lung, and
Ron Portman (2014)
10.3389/fonc.2014.00047
Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment
H. Haynes (2014)
10.1093/neuonc/not088
Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.
B. Alexander (2013)
10.7759/CUREUS.76
A MODEL FOR ACCELERATING IDENTIFICATION AND REGULATORY APPROVAL OF EFFECTIVE INVESTIGATIONAL AGENTS
L. Esserman (2012)
Simulating Gene Expression Data To Estimate Sample Size For Class and Biomarker Discovery
Jiexin Zhang (2012)
10.18632/oncotarget.22667
BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas
Shang-Pen Huang (2017)
10.1002/jat.3273
Rhamnose‐coated superparamagnetic iron‐oxide nanoparticles: an evaluation of their in vitro cytotoxicity, genotoxicity and carcinogenicity
Alessandro Paolini (2016)
10.1371/journal.pone.0149803
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Miranta Antoniou (2016)
10.1158/1078-0432.CCR-12-3722
Trial Designs for Personalizing Cancer Care: A Systematic Review and Classification
P. Tajik (2013)
10.3389/fonc.2015.00251
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence
H. Ellis (2015)
10.1053/j.seminoncol.2014.06.010
Medical management of high-grade astrocytoma: current and emerging therapies.
D. Johnson (2014)
Semantic Scholar Logo Some data provided by SemanticScholar